(2023)
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: Primary analysis in the original cohort of KGOG3046/TRU-D.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
11,
10
(2023)
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4.
NATURE COMMUNICATIONS.
14,
1
(2023)
Cross-Activation of Regulatory T Cells by Self Antigens Limits Self-Reactive and Activated CD8<SUP>+</SUP> T Cell Responses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
18
(2023)
Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko-EVE).
CANCER MEDICINE.
12,
7
(2023)
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
JOURNAL OF CLINICAL ONCOLOGY.
41,
3
(2023)
Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.
JOURNAL OF GYNECOLOGIC ONCOLOGY.
34,
1
(2023)
Arteriovenous Malformation Associated with Intravenous Leiomyomatosis of the Uterus: Characteristic CT Findings and Treatment by Embolization and Surgery.
Journal of Vascular and Interventional Radiology.
34,
1
(2022)
Invisible cervical cancers on MRI: Can the type of histology (SCC versus non-SCC) influence surgical planning?.
FRONTIERS IN ONCOLOGY.
12,
1
(2022)
Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER.
32,
12
(2022)
Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.
Gynecologic Oncology Reports.
42,
(2022)
The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching.
CANCERS.
14,
16
(2022)
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
JOURNAL OF GYNECOLOGIC ONCOLOGY.
33,
4
(2022)
Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
GYNECOLOGIC ONCOLOGY.
165,
3
(2022)
Prognostic Significance of HER3 Expression in Patients with Cervical Cancer.
CANCERS.
14,
9
(2022)
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
GYNECOLOGIC ONCOLOGY.
165,
1
(2022)
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/ NIRVANA-R trial.
JOURNAL OF GYNECOLOGIC ONCOLOGY.
33,
2
(2022)
Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY.
61,
2
(2022)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
EUROPEAN JOURNAL OF HUMAN GENETICS.
30,
3
(2022)
Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
CANCER RESEARCH.
82,
1
(2022)
Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival.
CANCER RESEARCH AND TREATMENT.
54,
1
단행본
(2015)
부인과학 (5판) Chapter 29. 상피성 난소암.
도서출판 고려의학.
공동
(2012)
종양학 (제4장 임신융모종양).
(주)일조각.
주저자
(2007)
부인과 수술.
고려의학.
공동
학술회의논문
(2018)
Role of secondary debulking in the era of target therapy - CON (15:45~16:00).
대한부인종양학회 제24차 추계심포지엄.
대한민국
(2017)
Clinical characteristics and outcomes of placental site trophoblastic tumor: Experience of single institution in Korea.
제103차 대한산부인과학회 학술대회.
대한민국
(2017)
Comparing efficacy between bevacizumab, paclitaxel, carboplatin triplet and combination chemotherapy in recurrent cervical cancer: Single center experience.
제103차 대한산부인과학회 학술대회.
대한민국
(2017)
Comparison of RNA-seq and microarray of gene expression signatures as a predictor of survival in six selected cancers.
제103차 대한산부인과학회 학술대회.
대한민국
(2017)
Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
제103차 대한산부인과학회 학술대회.
대한민국
(2017)
Differences in correlation of progression-free survival and overall survival by clinical variables in epithelial ovarian cancer.
25th Asian & Oceanic Congress of Obstetrics and Gynaecology.
홍콩
(2017)
Comparing outcome between paclitaxel/csplatin and paclitaxel/ifosfamide/cisplatin in recurrent.
제32차 대한부인종양학회 춘계학술대회.
대한민국
(2017)
Retrospective study of the efficacy of combination chemotherapy with Et-I in patients with heavily.
제32차 대한부인종양학회 춘계학술대회.
대한민국
(2015)
Prevalence study of germline BRCA1/2 mutation in Korean patients with ovarian cancer.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Differences in survival outcome of recurrent epithelial ovarian cancer patients with secondary cytoreductive surgery diagnosed recurrence by different initial diagnostic method.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Feasibility and outcomes of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
HER2 as a novel therapeutic target for cervical cancer.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
IGFBP-5 derived peptide as a novel angiogenesis inhibitor for treatment of ovarian cancer.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Outcomes of laparoscopic fertility-spariang surgery in presumed early-stage epithelial ovarian cancer.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Prognostic factors affecting survival in cervical cancer patients who had recurrent parenchymal lung lesion.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
The 4th Biennial Meeting of ASGO.
대한민국
(2015)
Gestational choriocarcinoma mimicking the degenerative uterine myoma in MRI finding.
제101차 대한산부인과학회 학술대회.
대한민국
(2015)
Glassy cell carcinoma of the uterine cervix: A rare case..
제101차 대한산부인과학회 학술대회.
대한민국
(2015)
HER2 as a Novel Therapeutic Target for Cervical Cancer.
제101차 대한산부인과학회 학술대회.
대한민국
(2015)
Sphingosing kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.
제101차 대한산부인과학회 학술대회.
대한민국
